Related Experiment Videos

Galectin-3: a novel mediator of heart failure development and progression

Rudolf A de Boer1, Adriaan A Voors, Pieter Muntendam

  • 1Department of Cardiology, University Medical Centre Groningen, PO Box 30.001, Hanzeplein 1, 9700 RB, Groningen, The Netherlands. r.a.de.boer@thorax.umcg.nl

European Journal of Heart Failure
|August 4, 2009
PubMed

Insights

Galectin-3, a key protein, is increasingly implicated in heart failure (HF) progression. Its levels correlate with cardiac fibrosis and patient prognosis, suggesting its potential as a biomarker for HF risk.

Area of Science:

  • Biochemistry
  • Immunology
  • Cardiology

Background:

  • Galectins are beta-galactoside-binding lectins involved in inflammation, immunity, and cancer.
  • Emerging evidence links galectin-3 to the pathophysiology of heart failure (HF).

Purpose of the Study:

  • To review recent advances in galectin-3 research concerning its role in heart failure development and progression.
  • To highlight galectin-3's potential as a prognostic biomarker in HF patients.

Main Methods:

  • Review of numerous studies on galectin-3 expression and function in cardiac remodeling.
  • Analysis of galectin-3's correlation with fibrosis, macrophage migration, and fibroblast proliferation in HF.

Main Results:

  • Galectin-3 is upregulated in hypertrophied hearts and promotes cardiac fibrosis.
  • Galectin-3 expression peaks during active fibrosis and diminishes upon recovery.
  • Elevated galectin-3 levels are associated with disease progression and poor prognosis in HF.

Conclusions:

  • Galectin-3 plays a significant role in the development and progression of heart failure.
  • Routine measurement of galectin-3 in HF patients may identify individuals at high risk for adverse outcomes, guiding personalized treatment strategies.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...